Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.